Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations

Cancer and Metastasis Reviews

Volumn 29, Issue SUPPL. 1, 2010, Pages

  Calvo, Emiliano ^a   Maroto, Pablo ^b   Del Muro, Xavier García ^c   Climent, Miguel Ángel ^d   González Larriba, José Luis ^e   Esteban, Emilio ^f   López, Rafael ^g   Paz Ares, Luis ^h   Bellmunt, Joaquim ⁱ   Castellano, Daniel ^j  

^a Hospital de Madrid CIOCC   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

Cancer treatment; Renal cell carcinoma; Spanish Oncology Genitourinary Group

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ZOLEDRONIC ACID;

ADVANCED CANCER; ASTHENIA; BONE METASTASIS; BRAIN METASTASIS; CANCER SURGERY; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GERIATRICS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY DISEASE; LIVER DISEASE; MEDICAL SOCIETY; MEDICAL SPECIALIST; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PERICARDIAL EFFUSION; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SPAIN; TACHYCARDIA; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); ETHNOLOGY; KIDNEY NEOPLASMS; PATHOLOGY; SECONDARY;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS;

EID: 77955426607     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-010-9232-5     Document Type: Review

References (62)

1. S Weikert H Boeing T Pischon, et al. 2008 Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition American Journal of Epidemiology 167 438 446 10.1093/aje/kwm321 18048375 (Pubitemid 351264143)
2. WT Lowrance RH Thompson DS Yee, et al. 2010 Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies BJU International 105 16 20 10.1111/j.1464-410X.2009.08706.x 19583732
3. E Bajetta A Gevorgyan H Mellstedt 2007 National integration of European standards Annals of Oncology 18 969 970 10.1093/annonc/mdm122 1:STN:280:DC%2BD2szntFGrsA%3D%3D 17586748 (Pubitemid 47050486)
4. MJ Harding J Paul CR Gillis, et al. 1993 Management of malignant teratoma: does referral to a specialist unit matter? Lancet 341 999 1002 10.1016/0140-6736(93)91082-W 1:STN:280:DyaK3s3isFOjtA%3D%3D 8096954 (Pubitemid 23109178)
5. HH Hansen DF Bajorin HB Muss, et al. 2004 Recommendations for a Global Core Curriculum in Medical Oncology Annals of Oncology 15 1603 1612 10.1093/annonc/mdh447 1:STN:280:DC%2BD2crkslSltA%3D%3D 15520060 (Pubitemid 39562599)
6. TE Hutson RA Figlin JG Kuhn, et al. 2008 Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies The Oncologist 13 1084 1096 10.1634/theoncologist.2008-0120 1:CAS:528: DC%2BD1cXhsVGgur7P 18838439
7. P Therasse A Le Cesne M Van Glabbeke, et al. 2005 RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma European Journal of Cancer 41 1426 1430 10.1016/j.ejca.2005.04.005 1:STN:280:DC%2BD2MzhsFKksw%3D%3D 15919202 (Pubitemid 40826466)
8. J Gralow RF Ozols DF Bajorin, et al. 2008 Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology Journal of Clinical Oncology 26 313 325 10.1200/JCO.2007.15.4088 18086794
9. ME Gore C Szczylik C Porta, et al. 2009 Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial The Lancet Oncology 10 757 763 10.1016/S1470-2045(09)70162-7 1:CAS:528:DC%2BD1MXptlalsrc%3D 19615940
10. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma The New England Journal of Medicine 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529 (Pubitemid 46089672)
11. T Eisen S Oudard C Szczylik, et al. 2008 Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial Journal of the National Cancer Institute 100 1454 1463 10.1093/jnci/djn319 1:CAS:528:DC%2BD1cXht1Oisb7J 18840822
12. Bajetta, E., Ravaud, A., Bracarda, S., et al. (2008). Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) 65 years with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 26:5095.
13. Dutcher, J. P., Szczylik, C., Tannir, N., et al. (2007). Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). ASCO Meeting Abstracts 25:5033.
14. Hutson, T. E., Calvo, E., Escudier, B. J., et al. (2010). Everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the RECORD-1 study. San Francisco: ASCO Genitourinary Cancers Symposium.
15. MH Chen 2009 Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue Current Cardiology Reports 11 167 174 10.1007/s11886-009-0025-9 1:CAS:528:DC%2BD1MXhsVClsr7P 19379636
16. FDA (2009). Bevacizumab (Avastin®)-full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125085s0168lbl.pdf.
17. Escudier, B. J., Bellmunt, J., Negrier, S., et al. (2009). Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV)∈+∈interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology (Meeting Abstracts) 27:5020.
18. B Escudier T Eisen WM Stadler, et al. 2009 Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial Journal of Clinical Oncology 27 3312 3318 10.1200/JCO.2008.19.5511 1:CAS:528:DC%2BD1MXpvFejt7w%3D 19451442
19. RJ Motzer TE Hutson P Tomczak, et al. 2009 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma Journal of Clinical Oncology 27 3584 3590 10.1200/JCO.2008.20.1293 1:CAS:528:DC%2BD1MXhtVOnu7nI 19487381
20. M Schmidinger CC Zielinski UM Vogl, et al. 2008 Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma Journal of Clinical Oncology 26 5204 5212 10.1200/JCO.2007.15.6331 18838713
21. RJ Motzer B Escudier S Oudard, et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D 18653228
22. G Hudes M Carducci P Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma The New England Journal of Medicine 356 2271 2281 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D 17538086 (Pubitemid 46849157)
23. BD Humphreys RJ Soiffer CC Magee 2005 Renal failure associated with cancer and its treatment: an update Journal of the American Society of Nephrology 16 151 161 10.1681/ASN.2004100843 15574506 (Pubitemid 43073167)
24. Gupta, S., Parsa, V., Heilbrun, L., et al. (2009). Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI). ASCO Meeting Abstracts 27:5108.
25. R Khosravan M Toh M Garrett, et al. 2010 Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function Journal of Clinical Pharmacology 50 472 481 10.1177/0091270009347868 1:CAS:528:DC%2BC3cXks1CltL4%3D 19779038
26. AA Miller DJ Murry K Owzar, et al. 2009 Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 Journal of Clinical Oncology 27 1800 1805 10.1200/JCO.2008.20.0931 1:CAS:528: DC%2BD1MXltlSis78%3D 19255312
27. RP Maroto H Villavicencio 2008 Sorafenib: tolerance in patients on chronic hemodialysis Oncology 74 245 10.1159/000151394
28. G Lunardi A Armirotti M Nicodemo, et al. 2009 Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series Clinical Therapeutics 31 1812 1819 10.1016/j.clinthera.2009.08.018 1:CAS:528:DC%2BD1MXht12gs7zI 19808140
29. J Bellmunt C Szczylik J Feingold, et al. 2008 Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features Annals of Oncology 19 1387 1392 10.1093/annonc/mdn066 1:STN:280:DC%2BD1cvotVGqsw%3D%3D 18385198
30. JF Castroagudín E Molina R Romero, et al. 2009 Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction Liver Transplantation 15 1792 1797 10.1002/lt.21920 19938140
31. J Moro L Almenar L Martínez-Dolz, et al. 2007 mTOR inhibitors: do they help preserve renal function? Transplantation Proceedings 39 2135 2137 10.1016/j.transproceed.2007.06.066 1:CAS:528:DC%2BD2sXhtVOgt7jO 17889116 (Pubitemid 47418173)
32. CL Bello M Garrett J Smeraglia, et al. 2009 Pharmacokinetics (PK) of sunitinib malate (SU11248) in subjects with hepatic impairment Annals of Oncology 17 148
33. EMEA (2009). Temsirolimus (Torisel®)-summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/torisel/emea- combined-h799en.pdf.
34. FDA (2007). Temsirolimus (Torisel®)-full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/022088lbl.pdf.
35. J Zekri N Ahmed RE Coleman, et al. 2001 The skeletal metastatic complications of renal cell carcinoma International Journal of Oncology 19 379 382 1:STN:280:DC%2BD3MzptFSmuw%3D%3D 11445855
36. TJ Polascik 2009 Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases Drug Design Development Therapy 3 27 40 1:CAS:528:DC%2BD1MXoslSmsLk%3D
37. A Lipton M Zheng J Seaman 2003 Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma Cancer 98 962 969 10.1002/cncr.11571 1:CAS:528:DC%2BD3sXns1Sjs74%3D 12942563 (Pubitemid 37022096)
38. C Christodoulou A Pervena G Klouvas, et al. 2009 Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone Oncology 76 209 211 10.1159/000201931 1:CAS:528:DC%2BD1MXis12gsb4%3D 19212145
39. RM Bukowski 2009 Prognostic factors for survival in metastatic renal cell carcinoma: update 2008 Cancer 115 2273 2281 10.1002/cncr.24226 1:CAS:528:DC%2BD1MXmtVOksbg%3D 19402065
40. G Schackert JE Price CD Bucana, et al. 1989 Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice International Journal of Cancer 44 892 897 10.1002/ijc.2910440524 1:STN:280:DyaK3c%2FmtFCltg%3D%3D (Pubitemid 20007989)
41. LS Kim S Huang W Lu, et al. 2004 Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice Clinical & Experimental Metastasis 21 107 118 10.1023/B:CLIN.0000024761. 00373.55 1:CAS:528:DC%2BD2cXjt1Clu7s%3D (Pubitemid 38988084)
42. S Yano H Shinohara RS Herbst, et al. 2000 Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis Cancer Research 60 4959 4967 1:CAS:528: DC%2BD3cXmsFWhsbk%3D 10987313
43. C Massard J Zonierek M Gross-Goupil, et al. 2009 Incidence of brain metastases in renal cell carcinoma treated with sorafenib Annals of Oncology 21 1027 1031 10.1093/annonc/mdp411 19850637
44. MM Walther B Patel PL Choyke, et al. 1997 Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation Journal d'Urologie 158 733 739 10.1016/S0022-5347(01)64303-9 1:STN:280:DyaK2svgt1KqsA%3D%3D
45. JE Montie BH Stewart RA Straffon, et al. 1977 The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma Journal d'Urologie 117 272 275 1:STN:280:DyaE2s7itFensA%3D%3D
46. SG Marcus PL Choyke R Reiter, et al. 1993 Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy Journal d'Urologie 150 463 466 1:STN:280:DyaK3szhs1eqsw%3D%3D
47. RC Flanigan SE Salmon BA Blumenstein, et al. 2001 Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer The New England Journal of Medicine 345 1655 1659 10.1056/NEJMoa003013 1:CAS:528:DC%2BD3MXovFKjt74%3D 11759643 (Pubitemid 33126820)
48. GH Mickisch A Garin H van Poppel, et al. 2001 Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966 970 10.1016/S0140-6736(01)06103-7 1:CAS:528:DC%2BD3MXntF2qtbw%3D 11583750 (Pubitemid 32913522)
49. RA Gatenby ET Gawlinski CM Tangen, et al. 2002 The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy Cancer Research 62 5218 5222 1:CAS:528:DC%2BD38Xnt1ynsL8%3D 12234987
50. B Escudier A Pluzanska P Koralewski, et al. 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111 10.1016/S0140-6736(07)61904-7 18156031 (Pubitemid 350296300)
51. C Szczylik C Porta S Bracarda, et al. 2008 Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology (Meeting Abstracts) 26 5124
52. T Logan DF McDermott JP Dutcher, et al. 2008 Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features Journal of Clinical Oncology (Meeting Abstracts) 26 5050
53. D Cho S Signoretti S Dabora, et al. 2007 Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma Clinical Genitourinary Cancer 5 379 385 10.3816/CGC.2007.n.020 1:CAS:528:DC%2BD2sXht1ert7nE 17956710
54. JC Rabets J Kaouk A Fergany, et al. 2004 Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma Urology 64 930 934 10.1016/j.urology.2004.06.052 15533480 (Pubitemid 39469508)
55. MM Walther JC Lyne SK Libutti, et al. 1999 Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study Urology 53 496 501 10.1016/S0090-4295(98)00562-7 1:STN:280:DyaK1M7psVSgtQ%3D%3D 10096373 (Pubitemid 29136191)
56. AJ Schrader PJ Olbert A Hegele, et al. 2008 Metastatic non-clear cell renal cell carcinoma: current therapeutic options BJU International 101 1343 1345 10.1111/j.1464-410X.2008.07462.x 1:CAS:528:DC%2BD1cXnsFOmsrg%3D 18241246 (Pubitemid 351623979)
57. JJ Patard E Leray N Rioux-Leclercq, et al. 2005 Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience Journal of Clinical Oncology 23 2763 2771 10.1200/JCO.2005.07.055 15837991 (Pubitemid 46179466)
58. AJ Schrader S Rauer-Bruening PJ Olbert, et al. 2009 Incidence and long-term prognosis of papillary renal cell carcinoma Journal of Cancer Research and Clinical Oncology 135 799 805 10.1007/s00432-008-0515-y 1:STN:280:DC%2BD1MzgvVOlug%3D%3D 19023595
59. S Störkel JN Eble K Adlakha, et al. 1997 Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) Cancer 80 987 989 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R 9307203 (Pubitemid 27360484)
60. Steiner, T., Roigas, J., Kirchner, H., et al. (2006). Clinical course of patients with metastatic papillary renal cell carcinoma. ASCO Meeting Abstracts 24:14591.
61. JP Dutcher P de Souza D McDermott, et al. 2009 Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies Medical Oncology 26 202 209 10.1007/s12032-009-9177-0 1:CAS:528:DC%2BD1MXmtVKitr0%3D 19229667
62. TK Choueiri A Plantade P Elson, et al. 2008 Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma Journal of Clinical Oncology 26 127 131 10.1200/JCO.2007.13.3223 1:CAS:528: DC%2BD1cXhsVCrtr4%3D 18165647